Walvax Biotechnology Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Walvax Biotechnology de 45.5% y 15.6% respectivamente, mientras que el BPA crecerá en un 45.1% al año.

Información clave

45.5%

Tasa de crecimiento de los beneficios

45.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	32.9%
Tasa de crecimiento de los ingresos	15.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Recent updates

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

Previsiones de crecimiento de beneficios e ingresos

SZSE:300142 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,717	1,261	N/A	N/A	1
12/31/2025	5,365	1,121	N/A	1,550	2
12/31/2024	4,132	781	N/A	973	1
3/31/2024	3,880	262	5	855	N/A
12/31/2023	4,114	419	188	1,134	N/A
9/30/2023	4,538	751	214	1,191	N/A
6/30/2023	4,906	763	158	1,185	N/A
3/31/2023	5,264	862	218	1,395	N/A
1/1/2023	5,086	729	110	1,201	N/A
9/30/2022	5,040	595	160	1,311	N/A
6/30/2022	4,461	530	-84	1,118	N/A
3/31/2022	3,685	434	-263	856	N/A
1/1/2022	3,463	428	-398	705	N/A
9/30/2021	3,501	932	-660	267	N/A
6/30/2021	3,715	1,261	-525	139	N/A
3/31/2021	3,260	1,053	-452	26	N/A
12/31/2020	2,939	1,003	-293	114	N/A
9/30/2020	1,890	457	-275	120	N/A
6/30/2020	1,194	119	-303	84	N/A
3/31/2020	1,057	85	-343	13	N/A
12/31/2019	1,121	142	-290	62	N/A
9/30/2019	1,098	1,444	-241	72	N/A
6/30/2019	1,000	1,426	-327	-44	N/A
3/31/2019	933	1,430	-265	-13	N/A
12/31/2018	874	1,415	-293	-65	N/A
9/30/2018	807	-407	-307	-81	N/A
6/30/2018	786	-421	-288	-62	N/A
3/31/2018	700	-484	-321	-14	N/A
12/31/2017	668	-537	N/A	-10	N/A
9/30/2017	628	265	N/A	70	N/A
6/30/2017	555	189	N/A	55	N/A
3/31/2017	466	83	N/A	-33	N/A
12/31/2016	591	70	N/A	-90	N/A
9/30/2016	692	-963	N/A	-153	N/A
6/30/2016	885	-936	N/A	-169	N/A
3/31/2016	1,045	-835	N/A	-133	N/A
12/31/2015	1,006	-841	N/A	-69	N/A
9/30/2015	843	182	N/A	-44	N/A
6/30/2015	731	138	N/A	-73	N/A
3/31/2015	705	147	N/A	-16	N/A
12/31/2014	719	143	N/A	-66	N/A
9/30/2014	816	-139	N/A	-149	N/A
6/30/2014	750	-91	N/A	-159	N/A
3/31/2014	676	-29	N/A	-149	N/A
12/31/2013	583	48	N/A	-122	N/A
9/30/2013	540	114	N/A	-2	N/A
6/30/2013	544	202	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (33.8% al año) de 300142 es superior a la tasa de ahorro (2.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (33.8% al año) de 300142 crezcan más rápidamente que el mercado CN (24% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 300142 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.6% al año) de 300142 crezcan más rápidamente que los del mercado CN (14.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13% al año) de 300142 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 300142 se prevé que sea elevada dentro de 3 años.

Walvax Biotechnology Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Consensus revenue estimates fall by 12%

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Recent updates

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

First quarter 2024 earnings: EPS and revenues miss analyst expectations

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Consensus revenue estimates fall by 12%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Price target decreased by 25% to CN¥25.50

Consensus revenue estimates fall by 21%

Price target decreased by 8.1% to CN¥34.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Price target increased by 19% to CN¥37.00

Price target decreased by 9.1% to CN¥30.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 16%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥32.00

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥36.00

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Consensus forecasts updated

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥48.62

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

Earnings released

New 90-day high - CN¥71.98

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento